Energy metabolism in the normal and in the diabetic heart

Current Pharmaceutical Design

Volumn 15, Issue 8, 2009, Pages 836-840

  Barsotti, Antonio ^a   Giannoni, Alberto ^a,b   Di Napoli, Pericle ^c   Emdin, Michele ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b CNR   (Italy)

^c Department of Cardiology   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 PHOSPHOFRUCTOKINASE; ACETYL COENZYME A CARBOXYLASE; FATTY ACID; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; TRIMETAZIDINE;

CARDIOMYOPATHY; CLINICAL TRIAL; ENERGY METABOLISM; ENERGY TRANSFER; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HEART DISEASE; HEART FAILURE; HEART MUSCLE METABOLISM; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; FATTY ACIDS, NONESTERIFIED; GLUCOSE; HEART DISEASES; HUMANS; INSULIN RESISTANCE; MYOCARDIAL ISCHEMIA; MYOCARDIUM; OXYGEN CONSUMPTION; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 65649098380     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787582066     Document Type: Review

References (58)

1. Knaapen P, Germans T, Knuuti J, Paulus WJ, Dijkmans PA, Allaart CP, et al. Myocardial energetics and efficiency: Current status of the noninvasive approach. Circulation 2007; 115: 918-27.
2. Taegtmeyer H. Energy metabolism of the heart: From basic concepts to clinical applications. Curr Probl Cardiol 1994; 19: 59-113.
3. Lopaschuk GD. Metabolic abnormalities in the diabetic heart. Heart Fail Rev 2002; 7: 149-59.
4. Neely JR, Rovetto MJ, Oram JF. Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis 1972; 15: 289-329.
5. Saddik M, Lopaschuk GD. Myocardial triglyceride turnover and contribution to energy substrate utilization in isolated working rat hearts. J Biol Chem 1991; 266: 8162-70.
6. McGarry JD, Woeltje KF, Kuwajima M, Foster DW. Regulation of ketogenesis and the renaissance of carnitine palmitoyltransferase. Diabetes Metab Rev 1989; 5: 271-84.
7. Tomlinson KC, Gardiner SM, Hebden RA, Bennett T. Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. Pharmacol Rev 1992; 44(1): 103-50.
8. Hamby RI, Zoneraich S, Sherman L. Diabetic cardiomyopathy. JAMA 1974; 229: 1749-54.
9. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007; 115: 3213-23.
10. Gøtzsche O. Myocardial cell dysfunction in diabetes meltitus. A review of clinical and experimental studies. Diabetes 1986; 35: 1158-62.
11. Lopaschuk GD. Abnormal mechanical function in diabetes: Relationship to altered myocardial carbohydrate/lipid metabolism. Coron Artery Dis 1996; 7: 116-23.
12. Stanley WC, Lopaschuk GD, Kivilo KM. Alterations in myocardial Energy metabolism in streptozotocin diabetes. In: McNeill JH, Ed. Experimental Models of Diabetes: CRC Press 1999: 19-38.
13. Wall SR, Lopaschuk GD. Glucose oxidation rates in fatty acid-perfused isolated working hearts from diabetic rats. Biochim Biophys Acta 1989; 1006: 97-103.
14. Saddik M, Gamble J, Witters LA, Lopaschuk GD. Acetyl-CoA carboxylase replation of fatty acid oxidation in the heart. J Biol Chem 1993; 268: 25836-45.
15. Kim KH, López-Casillas F, Bai DH, Luo X, Pape ME. Role of reversible phosphorylation of acetyl-CoA carboxylase in long-chain fatty acid synthesis. FASEB J 1989; 3: 2250-6.
16. Kennel WB, McGee DL. Diabetes and cardiovascular risk factors: The Framingham study. Circulation 1979; 59: 8-13.
17. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
18. Ulvenstam G, Aberg A, Bergstrand R, Johansson S, Pennert K, Vedin A, et al. Long-term prognosis after myocardial infarction in men with diabetes. Diabetes 1985; 34: 787-92.
19. Liu B, Clanachan AS, Schulz R, Lopaschuk GD. Cardiac efficiency is improved after ischemia by altering both the source and fate of protons. Circ Res 1996; 79: 940-8.
20. Liu B, el Alaoui-Talibi Z, Clanachan AS, Schulz R, Lopaschuk GD. Uncoupling of contractile function from mitochondrial TCA cycle activity and MVO2 during reperfusion of ischemic hearts. Am J Physiol 1996; 270: H72-80.
21. Liedtke AJ, DeMaison L, Eggleston AM, Cohen LM, Nellis SH. Changes in substrate metabolism and effects of excess fatty acids in reperfused myocardium. Circ Res 1988; 62: 535-42.
22. Huang XQ, Liedtke AJ. Alterations in fatty acid oxidation in ischemic and reperfused myocardium. Mol Cell Biochem 1989; 88(1-2): 145-53.
23. Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 1995; 270: 17513-20.
24. Dyck JR, Kudo N, Barr AJ, Davies SP, Hardie DG, Lopaschuk GD. Phosphorylation control of cardiac acetyl-CoA carboxylase by cAMP-dependent protein kinase and 5′-AMP activated protein kinase. Eur J Biochem 1999; 262: 184-90.
25. Lopaschuk GD, Spafford MA, Davies NJ, Wall SR. Glucose and palmitate oxidation in isolated working rat hearts reperfused after a period of transient global ischemia. Circ Res 1990; 66: 546-53.
26. Paulson DJ. The diabetic heart is more sensitive to ischemic injury. Cardiovasc Res 1997; 34: 104-12.
27. Haider B, Ahmed SS, Moschos CB, Oldewurtel HA, Regan TJ. Myocardial function and coronary blood flow response to acute ischemia in chronic canine diabetes. Circ Res 1977; 40: 577-83.
28. Hearse DJ, Stewart DA, Chain EB. Diabetes and the survival and recovery of the anoxic myocardium. J Mol Cell Cardiol 1975; 7: 397-415.
29. Savabi F, Kirsch A. Altered functional activity and anoxic tolerance in diabetic rat isolated atria. Arch Biochem Biophys 1990; 279: 183-7.
30. Ingebretsen CG, Moreau P, Hawelu-Johnson C, Ingebretsen WR Jr. Performance of diabetic rat hearts: Effects of anoxia and increased work. Am J Physiol 1980; 239: H614-20.
31. Lopaschuk GD, Tsang H. Metabolism of palmitate in isolated working hearts from spontaneously diabetic "BB" Wistar rats. Circ Res 1987; 61: 853-8.
32. Gamble J, Lopaschuk GD. Glycolysis and glucose oxidation during reperfusion of ischemic hearts from diabetic rats. Biochim Biophys Acta 1994; 1225: 191-9.
33. Pieper GM. Superoxide dismutase plus catalase improves post-ischaemic recovery in the diabetic heart. Cardiovasc Res 1988; 22: 916-26.
34. Benzi RH, Lerch R. Dissociation between contractile function and oxidative metabolism in postischemic myocardium. Attenuation by ruthenium red administered during reperfusion. Circ Res 1992; 71: 567-76.
35. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz RM. Thiazolidinediones, metformin, and outcomes in, older patients with diabetes and heart failure: An observational study. Circulation 2005; 111(5): 583-90.
36. Solang L, Malmerg K, Ryden L. Diabetes mellitus and congestive heart failure. Further Knowledge needed. Eur Heart J 1999; 20; 789-95.
37. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham study. Am J Cardiol 1974; 34: 29-34.
38. Fein FS, Sonnenblick EH. Diabetic cardiomyopathy. Prog Cardiovasc Dis 1985; 27: 255-70.
39. Zarich SW, Nesto RW. Diabetic cardiomyopathy. Am Heart J 1989; 118: 1000-12.
40. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-202.
41. Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, et al. Impact of diabetes on cardiac structure and function: The strong heart study. Circulation 2000; 101: 2271-6.
42. Tziakas DN, Chalikias GK, Kaski JC. Epidemiology of the diabetic heart. Coron Artery Dis 2005; 16(Suppl 1): S3-10.
43. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: Evidence, mechanisms, and therapeutic implications. Endocr Rev. 2004; 25: 543-67.
44. Paolisso G, Manzella D, Rizzo MR, Ragno E, Barbieri M, Varricchio G, et al. Elevated plasma fatty acid concentrations stimulate the cardiac autonomic nervous system in healthy subjects. Am J Clin Nutr 2000; 72: 723-30.
45. Marangou AG, Alford FP, Ward G, Liskaser F, Aitken PM, Weber KM, et al. Hormonal effects of norepinephrine on acute glucose disposal in humans: A minimal model analysis. Metabolism 1988; 37: 885-91.
46. Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation 1996; 93: 1667-76.
47. Cai L, Wang J, Li Y, Sun X, Wang L, Zhou Z, et al. Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. Diabetes 2005; 54(6): 1829-37.
48. Cesario DA, Brar R, Shivkumar K. Alterations in ion channel physiology in diabetic cardiomyopathy. Endocrinol Metab Clin North Am 2006; 35: 601-10.
49. The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J 2005; 26: 1115-40.
50. Barsotti A, Di Napoli P. Trimetazidine and cardioprotection during ischemia-reperfusion. Ital Heart J 2004; 5(Suppl 2): 29S-36.
51. Di Napoli P, Di Giovanni P, Gaeta MA, Taccardi AA, Barsotti A. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: A post hoc analysis of the Villa Pini d'Abruzzo. Trimetazidine Trial. J Cardiovasc Pharmacol 2007; 50: 585-9.
52. Di Napoli P, Di Giovanni P, Gaeta MA, D'Apotito G, Barsotti A.Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy. Am Heart J 2007; 154: 602.e1-5.
53. Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005; 91(2): 161-5.
54. Di Napoli P, Chierchia S, Taccardi AA, Grilli A, Felaco M, De Caterina R, et al. Trimetazidine improves post-ischemic recovery by preserving endothelial nitric oxide synthase expression in isolated working rat hearts. Nitric Oxide 2007; 16: 228-36.
55. Wolff AA, Rotmensch HH, Stanley WC, Ferrari R. Metabolic approaches to the treatment of ischemic heart disease: The clinicians' perspective. Heart Fail Rev 2002; 7: 187-203.
56. Crouser E, Exline M, Knoell D, Wewers MD. Sepsis: Links between pathogen sensing and organ damage. Curr Pharm Des 2008; 14(19): 1840-52.
57. ten Hove M, Neubauer S. The application of NMR spectroscopy for the study of heart failure. Curr Pharm Des 2008; 14(18): 1787-97.
58. Thompson CS. Animal models of diabetes mellitus: Relevance to vascular complications. Curr Pharm. Des 2008; 14(4): 309-24.